Sutro Biopharma, Inc.
HealthcareNASDAQ:STRO · NASDAQ Global Market
+$2.32 today
Vol 0.15M · Avg 0.27M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
144.3%
avg -61.1%
ROIC
-98.5%
avg -43.9%
ROA
-109.9%
avg -35.7%
Analysis
ROE is currently the strongest return metric at 144.3% versus its period average of -61.1%. 1 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Jane Chung | Chief Executive Officer & Director | $1.16M | — | 55 | $21,285.00 | 0.22% |
Hans-Peter Gerber | Chief Scientific Officer | $771,350.00 | — | 62 | $8,532.00 | 0.09% |
Edward C. Albini | Secretary | $629,660.00 | — | 68 | $4,594.00 | 0.05% |
Gregory K. Chow | Chief Financial Officer | $520,583.00 | — | 53 | $4,725.00 | 0.05% |
David Pauling | Chief Administrative Officer & General Counsel | — | — | 52 | $0.00 | <0.01% |
Jonathan Fawcett DPHIL MBBS | VP & Head of Clinical Development | — | — | — | — | — |
Regina Cheng | Vice President & Controller | — | — | — | — | — |
James R. Swartz | Founder | — | — | — | $10,000.00 | 0.10% |
Kari E. Leetch | Senior VP and Head of People & Culture | — | — | — | — | — |
Devendra Luhar | Senior Vice President of Technical Operations | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
5
$89,558.75
Sells
0
$0.00
Net Sentiment
+$89,558.75
Net buying
Most Active
Pauling David
1 transactions
Analysis
Insiders reported 5 buys worth $89,558.75 and 0 sells worth $0.00 over the last 12 months. That adds up to net buying of $89,558.75. Pauling David was the most active insider with 1 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A6 analysts |
| Revenue | N/A | N/A | -6.2% | +1.9% (10yr)7 analysts |
| Net Income | N/A | N/A | N/A | N/A7 analysts |
| EBIT | N/A | N/A | N/A | N/A7 analysts |
Analysis
Recent growth has been strongest in Revenue at -6.2% over three years. Forward estimates point to Revenue at +1.9% (10yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
Shattuck Labs, Inc.
NASDAQ:STTK
$236.64M
Artiva Biotherapeutics, Inc.
NASDAQ:ARTV
$211.08M
Connect Biopharma Holdings Limited
NASDAQ:CNTB
$133.48M
InflaRx N.V.
NASDAQ:IFRX
$115.57M
Adverum Biotechnologies, Inc.
ADVM
$96.26M
Kalaris Therapeutics Inc
NASDAQ:KLRS
$80.98M
Precision BioSciences, Inc.
NASDAQ:DTIL
$78.25M
Pliant Therapeutics, Inc.
NASDAQ:PLRX
$69.97M
Fractyl Health, Inc. Common Stock
NASDAQ:GUTS
$61.36M
Metagenomi, Inc. Common Stock
MGX
$45.18M
Who manages STRO?
Sutro Biopharma, Inc. (STRO) lists 10 active executives. The top listed executive is Gregory K. Chow, Chief Financial Officer.
Are STRO insiders buying or selling?
Recent insider activity shows net buying of $9.82M.
Explore More
Continue the stock analysis
Jump to another research area for this company.